Climb Bio (CLYM) CEO sells 30,902 shares after RSU vesting
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Climb Bio, Inc. President and CEO Aoife Brennan exercised restricted stock units and sold shares in a planned transaction. On June 27, 2026, 68,750 RSUs converted into the same number of common shares as part of a four-year vesting grant. On June 29, 2026, Brennan sold 30,902 common shares at a weighted average price of $13.17 per share pursuant to a Rule 10b5-1 trading plan to cover tax withholding obligations tied to the RSU vesting. After these transactions, Brennan directly owned 87,731 common shares, including 1,751 acquired through the employee stock purchase plan, and continued to hold RSUs scheduled to vest annually over four years.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 30,902 shares ($406,979)
Net Sell
3 txns
Insider
Brennan Aoife
Role
President and CEO
Sold
30,902 shs ($407K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 30,902 | $13.17 | $407K |
| Exercise | Restricted Stock Units | 68,750 | $0.00 | -- |
| Exercise | Common Stock | 68,750 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 87,731 shares (Direct, null);
Restricted Stock Units — 137,500 shares (Direct, null)
Footnotes (1)
- Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan. The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs. The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.
Key Figures
Shares sold: 30,902 shares
Weighted average sale price: $13.17 per share
RSUs converted: 68,750 units
+3 more
6 metrics
Shares sold
30,902 shares
Open-market sale on June 29, 2026
Weighted average sale price
$13.17 per share
Common stock sale range $13.02–$13.34
RSUs converted
68,750 units
RSUs converted into common stock on June 27, 2026
Shares owned after transactions
87,731 shares
Direct common stock holdings following June 29, 2026 sale
RSUs outstanding after conversion
137,500 RSUs
Restricted stock unit balance after June 27, 2026 transaction
ESPP shares included
1,751 shares
Employee Stock Purchase Plan shares within total holdings
Key Terms
Restricted Stock Units, Rule 10b5-1 trading plan, Employee Stock Purchase Plan, weighted average price, +1 more
5 terms
Restricted Stock Units financial
"The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Rule 10b5-1 trading plan regulatory
"The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Purchase Plan financial
"Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
weighted average price financial
"The price reported is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
vesting financial
"are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transactions did Climb Bio (CLYM) report for Aoife Brennan?
Climb Bio reported that President and CEO Aoife Brennan exercised 68,750 restricted stock units into common shares, then sold 30,902 shares in an open-market transaction under a Rule 10b5-1 trading plan to address tax withholding obligations from the RSU vesting.
What are the vesting terms of the Climb Bio (CLYM) CEO’s restricted stock units?
The restricted stock units were granted on June 27, 2024 and are scheduled to vest over four years. Twenty-five percent of the RSUs vest on each of the first four anniversaries of the grant date, conditioned on Aoife Brennan’s continued service with the company.
How many restricted stock units did the Climb Bio (CLYM) CEO convert?
Aoife Brennan converted 68,750 restricted stock units into an equal number of Climb Bio common shares. Each RSU represents a contingent right to receive one share, and the conversion reflects vesting under a previously granted equity award with multi-year vesting terms.